PAVmed Inc represents a set of core values and corporate philosophy that drive its operations. The company prioritizes innovation, seeking to develop and commercialize cutting-edge medical devices and technologies. PAVmed Inc is dedicated to enhancing patient outcomes and providing effective healthcare solutions. The company also focuses on efficiency and cost-effectiveness, aiming to deliver products and services that maximize value for patients, healthcare providers, and other stakeholders. PAVmed Inc values collaboration and partnerships, working with industry experts, physicians, and other key stakeholders to foster advancements in medical technology. Overall, the company strives to uphold its commitment to innovation, efficiency, and collaboration in the healthcare industry.

PAVmed Inc is primarily present in the United States.

PAVmed Inc has achieved several significant milestones. Some notable accomplishments include the successful launch and commercialization of its innovative medical devices. The company introduced CarpX, a minimally invasive device for carpal tunnel syndrome, which received 510(k) clearance from the FDA. PAVmed also achieved the FDA clearance for its EsoGuard esophageal DNA test, revolutionizing the detection of esophageal cancer. Additionally, the company expanded its product portfolio with the acquisition of Solys Medical, broadening its presence in the urology market. PAVmed Inc continues to make strides in advancing healthcare through groundbreaking technologies and strategic partnerships.

PAVmed Inc is a medical device company that focuses on the development and commercialization of innovative products in the healthcare sector. Founded in 2014, PAVmed Inc has aimed to address unmet medical needs through its proprietary technologies and collaborations with renowned medical institutions. With a diverse portfolio encompassing devices and procedures across different specialties, the company is committed to improving patient outcomes and enhancing healthcare delivery. PAVmed Inc has steadily grown its presence in the medical industry and continues to strive towards developing groundbreaking solutions to improve the quality of patient care.

The main competitors of PAVmed Inc in the market include companies like Johnson & Johnson, Medtronic, Boston Scientific Corporation, and Integra Lifesciences Holdings Corporation.

PAVmed Inc is primarily active in the medical technology industry.

PAVmed Inc is a medical technology company focused on developing and commercializing innovative products for the healthcare industry. The company's business model revolves around identifying unmet medical needs and creating innovative solutions to address them. PAVmed focuses on the development and commercialization of medical devices and technologies that have the potential to significantly improve patient outcomes and revolutionize the healthcare sector. Through strategic partnerships, acquisitions, and internal research and development, PAVmed Inc aims to bring cutting-edge products to market and provide value to patients, physicians, and healthcare providers.

PAVmed P/E suhe on −0,13.

PAVmed KUV on 1,63.

AlleAktien kvaliteediskoor ettevõttele PAVmed on 5/10.

oodatud PAVmed käive on 4,83 mln. USD.

oodatud PAVmed kasum on −62,81 mln. USD.

PAVmed Inc. is an American company specializing in the development of medical devices and products. Their business model includes various divisions targeting the needs of different markets. The company focuses on developing innovative medical technology solutions that solve problems for patients and doctors. One of PAVmed's key divisions is the development of medical devices, such as the CarpX™ technology for minimally invasive hand surgery or the PortIO™ system designed for quick, secure, and hygienic access to the bloodstream in chemotherapy patients. PAVmed works closely with certified surgeons and physicians to develop devices that meet the highest standards to ensure optimal patient care. Another important division of PAVmed is the development of healthcare products. These include the NextCath system, which enables safe and easy catheterization, and the DisappEAR ear spray, which treats and prevents acute ear infections. PAVmed's healthcare products aim to improve patients' quality of life while also facilitating the work of medical professionals. PAVmed also operates an IT division specializing in the development of software solutions for the medical industry. These include the analysis of diagnostic data, organization of patient data, and the development of virtual treatment options. PAVmed has also developed an electronic patient record to provide patients with a clearer overview of their medical history and improve information exchange between doctors and patients. PAVmed relies on partnerships and collaborations to strengthen its business model and drive the development of innovative solutions. The company works closely with other medical technology companies, universities, and research institutions to create synergies and accelerate the development of new technologies and products. PAVmed's business model is based on researching and developing high-quality and innovative solutions for the healthcare industry. Through close collaboration with experienced professionals and the use of the latest technologies, PAVmed has been able to develop a wide portfolio of products and services tailored to the specific needs of different markets. The company relies on partnerships and collaborations to achieve synergistic effects and focuses on meeting the highest quality standards. In this way, PAVmed offers a wide range of solutions for the needs of patients and medical professionals.

PAVmed maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu PAVmed jaoks arvutada või ettevõte ei maksa dividende välja.

PAVmed ISIN on US70387R1068.

PAVmed WKN on A2AQDJ.

PAVmed tähis on PAVM.

Viimase 12 kuu jooksul maksis PAVmed dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab PAVmed tõenäoliselt dividendi summas 0 USD.

PAVmed praegune dividenditootlus on .

PAVmed maksab kvartaalset dividendi. See makstakse välja kuudel .

PAVmed maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

PAVmed on liigitatud sektorisse 'Tervis'.

Viimase PAVmed dividendide saamiseks 8.9.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 8.9.2024.

Viimane dividendimakse toimus 8.9.2024.

Aastal 2023 maksis PAVmed 0 USD dividende.

PAVmed dividendid makstakse välja USD.